{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:13:43Z","timestamp":1794003223710,"version":"4.8.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471623"],"award-info":[{"award-number":["82471623"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170852"],"award-info":[{"award-number":["82170852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04976-9","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:34:44Z","timestamp":1780695284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PROTAC-mediated PCSK9 degradation attenuates atherosclerosis and improves plaque composition via suppression of NF-\u03baB\/TNF-\u03b1 pathway"],"prefix":"10.1186","volume":"24","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-die","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-ming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-han","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"4976_CR1","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.2538","volume":"17","author":"C Weber","year":"2011","unstructured":"Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410\u201322.","journal-title":"Nat Med"},{"key":"4976_CR2","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.3390\/ijms18102034","volume":"18","author":"M-Y Wu","year":"2017","unstructured":"Wu M-Y, Li C-J, Hou M-F, Chu P-Y. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci. 2017;18:2034.","journal-title":"Int J Mol Sci"},{"key":"4976_CR3","doi-asserted-by":"publisher","DOI":"10.34133\/research.0922","volume":"8","author":"Y Cui","year":"2025","unstructured":"Cui Y, Chen Y, Li H, Zhang W, Wang X, Xia M, et al. PCSK9 promotes atherosclerotic plaque instability by inducing VSMC ferroptosis through the YAP1-NUPR1 axis. Research. 2025;8:0922.","journal-title":"Research"},{"key":"4976_CR4","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.3390\/ijms23063346","volume":"23","author":"S Jebari-Benslaiman","year":"2022","unstructured":"Jebari-Benslaiman S, Galicia-Garc\u00eda U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022;23:3346.","journal-title":"Int J Mol Sci"},{"key":"4976_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5245308","volume":"2020","author":"C Khatana","year":"2020","unstructured":"Khatana C, Saini NK, Chakrabarti S, Saini V, Sharma A, Saini RV, et al. Mechanistic insights into the oxidized low-density lipoprotein-induced atherosclerosis. Oxid Med Cell Longev. 2020;2020:5245308.","journal-title":"Oxid Med Cell Longev"},{"key":"4976_CR6","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","volume":"132","author":"N Bergeron","year":"2015","unstructured":"Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Proprotein convertase subtilisin\/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132:1648\u201366.","journal-title":"Circulation"},{"key":"4976_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156485","volume":"176","author":"G Fan","year":"2026","unstructured":"Fan G, Guo W, Lu J, He Y, Zha J, Zhang Q, et al. CADD-engineered peptide protacs efficiently target PCSK9 for hypercholesterolemia in vivo. Metabolism. 2026;176:156485.","journal-title":"Metabolism"},{"key":"4976_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13459","volume":"51","author":"R Ragusa","year":"2021","unstructured":"Ragusa R, Basta G, Neglia D, De Caterina R, Del Turco S, Caselli C. PCSK9 and atherosclerosis: looking beyond LDL regulation. Eur J Clin Invest. 2021;51:e13459.","journal-title":"Eur J Clin Invest"},{"key":"4976_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5551\/jat.RV17003","volume":"24","author":"MD Shapiro","year":"2017","unstructured":"Shapiro MD, Fazio S. PCSK9 and atherosclerosis - lipids and beyond. J Atheroscler Thromb. 2017;24:462\u201372.","journal-title":"J Atheroscler Thromb"},{"key":"4976_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/ATVBAHA.123.320391","volume":"45","author":"Z Peng","year":"2025","unstructured":"Peng Z, Lv SJ, Chen H, Rao H, Guo Z, Wan Q, et al. Disruption of PCSK9 suppresses inflammation and attenuates abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2025;45:e1\u2013e14.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4976_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46336-2","volume":"15","author":"D Shin","year":"2024","unstructured":"Shin D, Kim S, Lee H, Lee H-C, Lee J, Park H-W, et al. PCSK9 stimulates Syk, PKC\u03b4, and NF-\u03baB, leading to atherosclerosis progression independently of LDL receptor. Nat Commun. 2024;15:2789.","journal-title":"Nat Commun"},{"key":"4976_CR12","first-page":"691","volume":"17","author":"D Tan","year":"2025","unstructured":"Tan D, Yang X, Yang J, Fan G, Xiong G. PCSK9 in vascular aging and age-related diseases. Aging Dis. 2025;17:691\u2013711.","journal-title":"Aging Dis"},{"key":"4976_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11883-013-0310-3","volume":"15","author":"EA Stein","year":"2013","unstructured":"Stein EA, Swergold GD. Potential of proprotein convertase subtilisin\/kexin type 9 based therapeutics. Curr Atheroscler Rep. 2013;15:310.","journal-title":"Curr Atheroscler Rep"},{"key":"4976_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-91061-5","volume":"15","author":"YF Cui","year":"2025","unstructured":"Cui YF, Chen XC, Mijiti T, Abudurusuli A, Deng LH, Ma X, et al. PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPAR\u03b1 expression. Sci Rep. 2025;15:6941.","journal-title":"Sci Rep"},{"key":"4976_CR15","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1016\/j.ymthe.2022.08.024","volume":"30","author":"I Hetherington","year":"2022","unstructured":"Hetherington I, Totary-Jain H. Anti-atherosclerotic therapies: milestones, challenges, and emerging innovations. Mol Ther. 2022;30:3106\u201317.","journal-title":"Mol Ther"},{"key":"4976_CR16","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","volume":"62","author":"D Urban","year":"2013","unstructured":"Urban D, P\u00f6ss J, B\u00f6hm M, Laufs U. Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62:1401\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"4976_CR17","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1194\/jlr.M053207","volume":"55","author":"B Ason","year":"2014","unstructured":"Ason B, van der Hoorn JW, Chan J, Lee E, Pieterman EJ, Nguyen KK, et al. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J Lipid Res. 2014;55:2370\u20139.","journal-title":"J Lipid Res"},{"key":"4976_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1415668","volume":"11","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Wang Y, Ma S, Qian L, Jing Y, Chen X, et al. Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis. Front Cardiovasc Med. 2024;11:1415668.","journal-title":"Front Cardiovasc Med"},{"key":"4976_CR19","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507\u201319.","journal-title":"N Engl J Med"},{"key":"4976_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.595819","volume":"11","author":"JL Katzmann","year":"2020","unstructured":"Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 Inhibition: insights from clinical trials and future prospects. Front Physiol. 2020;11:595819.","journal-title":"Front Physiol"},{"key":"4976_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/phar.4635","volume":"45","author":"CL Garwood","year":"2025","unstructured":"Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: a state-of-the-art review. Pharmacotherapy. 2025;45:54\u201365.","journal-title":"Pharmacotherapy"},{"key":"4976_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/genes14030632","volume":"14","author":"T Levstek","year":"2023","unstructured":"Levstek T, Karun T, Rehberger Likozar A, \u0160ebe\u0161tjen M, Trebu\u0161ak Podkraj\u0161ek K. Interplay between microRNAs, serum proprotein convertase Subtilisin\/Kexin type 9 (PCSK9), and lipid parameters in patients with very high Lipoprotein(a) treated with PCSK9 inhibitors. Genes. 2023;14:632.","journal-title":"Genes"},{"key":"4976_CR23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jacc.2021.07.056","volume":"78","author":"C Oleaga","year":"2021","unstructured":"Oleaga C, Shapiro MD, Hay J, Mueller PA, Miles J, Huang C, et al. Hepatic sensing loop regulates PCSK9 secretion in response to inhibitory antibodies. J Am Coll Cardiol. 2021;78:1437\u201349.","journal-title":"J Am Coll Cardiol"},{"key":"4976_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-020-01009-4","volume":"19","author":"Y Tang","year":"2020","unstructured":"Tang Y, Li SL, Hu JH, Sun KJ, Liu LL, Xu DY. Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. Cardiovas Diabetol. 2020;19:33.","journal-title":"Cardiovas Diabetol"},{"key":"4976_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2026.103027","volume":"115","author":"G Fan","year":"2026","unstructured":"Fan G, Zhang Q, Guo W, Liu M, Tan D, Tang Z, et al. Proteolysis-targeting chimera (PROTAC): a promising senolytic strategy. Ageing Res Rev. 2026;115:103027.","journal-title":"Ageing Res Rev"},{"key":"4976_CR26","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41401-024-01305-9","volume":"45","author":"WZ Wang","year":"2024","unstructured":"Wang WZ, Liu C, Luo JQ, Lei LJ, Chen MH, Zhang YY, et al. A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis. Acta Pharmacol Sin. 2024;45:2119\u201333.","journal-title":"Acta Pharmacol Sin"},{"key":"4976_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","volume":"7","author":"M He","year":"2022","unstructured":"He M, Cao C, Ni Z, Liu Y, Song P, Hao S, et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduct Target Ther. 2022;7:181.","journal-title":"Signal Transduct Target Ther"},{"key":"4976_CR28","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/17460441.2019.1659242","volume":"14","author":"M Konstantinidou","year":"2019","unstructured":"Konstantinidou M, Li J, Zhang B, Wang Z, Shaabani S, Ter Brake F, et al. PROTACs- a game-changing technology. Expert Opin Drug Discov. 2019;14:1255\u201368.","journal-title":"Expert Opin Drug Discov"},{"key":"4976_CR29","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.str.2022.05.014","volume":"30","author":"V Jackson","year":"2022","unstructured":"Jackson V, Hermann J, Tynan CJ, Rolfe DJ, Corey RA, Duncan AL, et al. The guidance and adhesion protein FLRT2 dimerizes in cis via dual small-X(3)-small transmembrane motifs. Structure. 2022;30:1354\u201365.e5.","journal-title":"Structure"},{"key":"4976_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","volume":"31","author":"M Pettersson","year":"2019","unstructured":"Pettersson M, Crews CM. PROteolysis TArgeting chimeras (PROTACs) - past, present and future. Drug Discov Today Technol. 2019;31:15\u201327.","journal-title":"Drug Discov Today Technol"},{"key":"4976_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116901","volume":"279","author":"J Liu","year":"2024","unstructured":"Liu J, Liu Y, Tang J, Gong Q, Yan G, Fan H, et al. Recent advances in dual PROTACs degrader strategies for disease treatment. Eur J Med Chem. 2024;279:116901.","journal-title":"Eur J Med Chem"},{"key":"4976_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s43556-025-00369-1","volume":"6","author":"G Fan","year":"2025","unstructured":"Fan G, Zha J, Chen S, Cang P, Zhang Q, Yang J, et al. Computer-aided design enables repurposing of proprotein convertase subtilisin\/kexin type 9 degrader from cholesterol-lowering to colon cancer therapy. Mol Biomed. 2025;6:120.","journal-title":"Mol Biomed"},{"key":"4976_CR33","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1194\/jlr.M051326","volume":"55","author":"S K\u00fchnast","year":"2014","unstructured":"K\u00fchnast S, van der Hoorn JW, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014;55:2103\u201312.","journal-title":"J Lipid Res"},{"key":"4976_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40256-016-0166-3","volume":"16","author":"SL Greig","year":"2016","unstructured":"Greig SL, Deeks ED. Alirocumab: a review in hypercholesterolemia. Am J Cardiovas Drugs. 2016;16:141\u201352.","journal-title":"Am J Cardiovas Drugs"},{"key":"4976_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28692-z","volume":"13","author":"H Gao","year":"2022","unstructured":"Gao H, Zhou L, Zhong Y, Ding Z, Lin S, Hou X, et al. Kindlin-2 haploinsufficiency protects against fatty liver by targeting Foxo1 in mice. Nat Commun. 2022;13:1025.","journal-title":"Nat Commun"},{"key":"4976_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41420-024-02107-y","volume":"10","author":"S Ouyang","year":"2024","unstructured":"Ouyang S, Xiang S, Wang X, Yang X, Liu X, Zhang M, et al. The downregulation of SCGN induced by lipotoxicity promotes NLRP3-mediated \u03b2-cell pyroptosis. Cell Death Discov. 2024;10:340.","journal-title":"Cell Death Discov"},{"key":"4976_CR37","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf022","volume":"9","author":"X Liu","year":"2025","unstructured":"Liu X, Liu X, Hu Y, Wang X, Yang X, Yan B, et al. Secretagogin is highly expressed in enteroendocrine K cells and plays a critical role in nutrient-induced GIP secretion. J Endocr Soc. 2025;9:bvaf022.","journal-title":"J Endocr Soc"},{"key":"4976_CR38","first-page":"1499","volume":"15","author":"QT Luo","year":"2024","unstructured":"Luo QT, Ye YC, Guo WM, Zhu Q, Wang SS, Li N, et al. Senolytic treatment improve small intestine regeneration in aging. Aging Dis. 2024;15:1499\u2013507.","journal-title":"Aging Dis"},{"key":"4976_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13134","volume":"19","author":"G Fan","year":"2020","unstructured":"Fan G, Ka\u00dfmann M, Cui Y, Matthaeus C, Kunz S, Zhong C, et al. Age attenuates the T-type Ca(V) 3.2-RyR axis in vascular smooth muscle. Aging Cell. 2020;19:e13134.","journal-title":"Aging Cell"},{"key":"4976_CR40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.vph.2018.08.002","volume":"112","author":"EM Maguire","year":"2019","unstructured":"Maguire EM, Pearce SWA, Xiao Q. Foam cell formation: a new target for fighting atherosclerosis and cardiovascular disease. Vasc Pharmacol. 2019;112:54\u201371.","journal-title":"Vasc Pharmacol"},{"key":"4976_CR41","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nm1209-1357","volume":"15","author":"X Liu","year":"2009","unstructured":"Liu X, Ntambi JM. Atherosclerosis: keep your macrophages in shape. Nat Med. 2009;15:1357\u20138.","journal-title":"Nat Med"},{"key":"4976_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/MOL.0000000000000574","volume":"30","author":"CS Pryma","year":"2019","unstructured":"Pryma CS, Ortega C, Dubland JA, Francis GA. Pathways of smooth muscle foam cell formation in atherosclerosis. Curr Opin Lipidol. 2019;30:117\u201324.","journal-title":"Curr Opin Lipidol"},{"key":"4976_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41392-022-00955-7","volume":"7","author":"P Kong","year":"2022","unstructured":"Kong P, Cui Z-Y, Huang X-F, Zhang D-D, Guo R-J, Han M. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther. 2022;7:131.","journal-title":"Signal Transduct Target Ther"},{"key":"4976_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.707529","volume":"8","author":"K Malekmohammad","year":"2021","unstructured":"Malekmohammad K, Bezsonov EE, Rafieian-Kopaei M. Role of lipid accumulation and inflammation in atherosclerosis: focus on molecular and cellular mechanisms. Front Cardiovasc Med. 2021;8:707529.","journal-title":"Front Cardiovasc Med"},{"key":"4976_CR45","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","volume":"125","author":"M Denis","year":"2012","unstructured":"Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, et al. Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012;125:894\u2013901.","journal-title":"Circulation"},{"key":"4976_CR46","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.atherosclerosis.2016.08.007","volume":"253","author":"B Cariou","year":"2016","unstructured":"Cariou B, Ding Z, Mehta JL. PCSK9 and atherosclerosis: beyond LDL-cholesterol lowering. Atherosclerosis. 2016;253:275\u20137.","journal-title":"Atherosclerosis"},{"key":"4976_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.06.971","volume":"378","author":"R Marfella","year":"2023","unstructured":"Marfella R, Prattichizzo F, Sardu C, Paolisso P, D\u2019Onofrio N, Scisciola L, et al. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Atherosclerosis. 2023;378:117180.","journal-title":"Atherosclerosis"},{"key":"4976_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108480","volume":"249","author":"S Hummelgaard","year":"2023","unstructured":"Hummelgaard S, Vilstrup JP, Gustafsen C, Glerup S, Weyer K. Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther. 2023;249:108480.","journal-title":"Pharmacol Ther"},{"key":"4976_CR49","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/aps.2016.134","volume":"38","author":"NY He","year":"2017","unstructured":"He NY, Li Q, Wu CY, Ren Z, Gao Y, Pan LH, et al. Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives. Acta Pharmacol Sin. 2017;38:301\u201311.","journal-title":"Acta Pharmacol Sin"},{"key":"4976_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcph.766","volume":"57","author":"MK Ito","year":"2017","unstructured":"Ito MK, Santos RD. PCSK9 inhibition with monoclonal antibodies: modern management of hypercholesterolemia. J Clin Pharmacol. 2017;57:7\u201332.","journal-title":"J Clin Pharmacol"},{"key":"4976_CR51","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s11883-022-01053-3","volume":"24","author":"I Gouni-Berthold","year":"2022","unstructured":"Gouni-Berthold I, Schwarz J, Berthold HK. PCSK9 monoclonal antibodies: new developments and their relevance in a nucleic acid-based therapy era. Curr Atheroscler Rep. 2022;24:779\u201390.","journal-title":"Curr Atheroscler Rep"},{"key":"4976_CR52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jacbts.2017.12.001","volume":"3","author":"WS Weintraub","year":"2018","unstructured":"Weintraub WS, Lee KH. Advances in cardiovascular care: how to stimulate innovation while controlling cost. JACC Basic Transl Sci. 2018;3:114\u20138.","journal-title":"JACC Basic Transl Sci"},{"key":"4976_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10565-019-09497-1","volume":"36","author":"M Haeussler","year":"2020","unstructured":"Haeussler M. CRISPR off-targets: a question of context. Cell Biol Toxicol. 2020;36:5\u20139.","journal-title":"Cell Biol Toxicol"},{"key":"4976_CR54","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1093\/nar\/gku402","volume":"42","author":"Y Lin","year":"2014","unstructured":"Lin Y, Cradick TJ, Brown MT, Deshmukh H, Ranjan P, Sarode N, et al. CRISPR\/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 2014;42:7473\u201385.","journal-title":"Nucleic Acids Res"},{"key":"4976_CR55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21:181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"key":"4976_CR56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/cvr\/cvw053","volume":"110","author":"H Tavori","year":"2016","unstructured":"Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, et al. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc Res. 2016;110:268\u201378.","journal-title":"Cardiovasc Res"},{"key":"4976_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1476-511X-13-136","volume":"13","author":"YH Li","year":"2014","unstructured":"Li YH, Liu L. Apolipoprotein E synthesized by adipocyte and apolipoprotein E carried on lipoproteins modulate adipocyte triglyceride content. Lipids Health Dis. 2014;13:136.","journal-title":"Lipids Health Dis"},{"key":"4976_CR58","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1021\/acs.jmedchem.3c00585","volume":"66","author":"B Zhang","year":"2023","unstructured":"Zhang B, Liu C, Yang Z, Zhang S, Hu X, Li B, et al. Discovery of BWA-522, a first-in-class and orally bioavailable PROTAC degrader of the androgen receptor targeting N-terminal domain for the treatment of prostate cancer. J Med Chem. 2023;66:11158\u201386.","journal-title":"J Med Chem"},{"key":"4976_CR59","doi-asserted-by":"publisher","first-page":"14277","DOI":"10.1021\/acs.jmedchem.4c01104","volume":"67","author":"Y He","year":"2024","unstructured":"He Y, Zheng Y, Zhu C, Lei P, Yu J, Tang C, et al. Radioactive ADME demonstrates ARV-110\u2019s high druggability despite low oral bioavailability. J Med Chem. 2024;67:14277\u201391.","journal-title":"J Med Chem"},{"key":"4976_CR60","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood.2023022993","volume":"143","author":"JML Casan","year":"2024","unstructured":"Casan JML, Seymour JF. Degraders upgraded: the rise of PROTACs in hematological malignancies. Blood. 2024;143:1218\u201330.","journal-title":"Blood"},{"key":"4976_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177499","volume":"998","author":"EI Ahmed","year":"2025","unstructured":"Ahmed EI, Moneam Shamardl HA, Elsayed AM, Sadik SA. Evolocumab ameliorates myocardial fibrosis and improves metabolic syndrome-induced cardiac dysfunction in rats via inhibiting PCSK9\/NLRP3 inflammasome and Caspase-1 \/ IL-1\u03b2 pathways. Eur J Pharmacol. 2025;998:177499.","journal-title":"Eur J Pharmacol"},{"key":"4976_CR62","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1080\/15548627.2023.2234797","volume":"19","author":"L Mei","year":"2023","unstructured":"Mei L, Chen X, Wei F, Huang X, Liu L, Yao J, et al. Tethering ATG16L1 or LC3 induces targeted autophagic degradation of protein aggregates and mitochondria. Autophagy. 2023;19:2997\u20133013.","journal-title":"Autophagy"},{"key":"4976_CR63","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1021\/jacs.1c00451","volume":"143","author":"J Liu","year":"2021","unstructured":"Liu J, Chen H, Liu Y, Shen Y, Meng F, Kaniskan H, et al. Cancer selective target degradation by folate-caged PROTACs. J Am Chem Soc. 2021;143:7380\u20137.","journal-title":"J Am Chem Soc"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04976-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04976-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04976-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:04:04Z","timestamp":1786532644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04976-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4976"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04976-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Institutional Animal Care and Use Committee of TOPBIOTECH Shenzhen, China (Ethical Approval Number: TOP-IACUC-2024-0144).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"434"}}